Mårten Falkenberg/ Vascular News
Aug 31, 2025, 07:12
Late-Breaking SWEDEPAD Trial Finds No Benefit of Drug-Coated Balloons and Stents, Raises Safety Concerns
Vascular News shared an important post on LinkedIn:
“BREAKING NEWS: Drug-coated balloons and stents were not associated with reduced risk of amputation or improved quality of life compared with uncoated devices in the SWEDEPAD 1 and 2 trials. In addition, higher five-year mortality with drug-coated devices in patients with intermittent claudication was noted, leading researchers to stress that the safety of paclitaxel-coated devices is an “ongoing discussion”.
These late-breaking findings were presented today at the European Society of Cardiology (ESC) 2025 congress (29 August–1 September, Madrid, Spain) and simultaneously published in The Lancet Group.”
Read more here.
Stay updated with Hemostasis Today.
-
Mar 8, 2026, 16:19Simon Senanu: Crossmatch Procedures and Advanced Troubleshooting
-
Mar 8, 2026, 15:53Stuart Diamond: ApoB as a Key Marker of Cardiovascular Risk
-
Mar 8, 2026, 15:49Wolfgang Miesbach: Discussing Immunological Challenges in Hemophilia at GTH 2026
-
Mar 8, 2026, 15:41George Sands: AI Screening Tool for Early Detection of Heart Disease
-
Mar 8, 2026, 15:26Hussien Hishmat: The 2026 Guide to Pulmonary Embolism – Diagnosis Decoded
-
Mar 8, 2026, 15:01Raluca Simbotin: How We Care for Complex Patients Is A Measure of Healthcare System Maturity
-
Mar 8, 2026, 14:09Frederik Denorme։ PhD Position in Translational Stroke Research at the University of Antwerp
-
Mar 8, 2026, 14:03Akinchan Bhardwaj: Will Plaque Imaging Eventually Reshape Preventive Cardiology Workflows?
-
Mar 8, 2026, 14:00Hisam Siddiqi: A Helpful Clinical Framework for Understanding Eosinophilia